# Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

> **NCT03799627** · PHASE2 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 175 (actual)

## Conditions studied

- Anemia
- Dialysis-dependent Chronic Kidney Disease

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Epoetin Alfa
- **DRUG:** Vadadustat TIW

## Key facts

- **NCT ID:** NCT03799627
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-07-15
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799627, "Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03799627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*